Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Medifast ( (MED) ).
On June 18, 2025, Medifast held its Annual Meeting where stockholders voted on several proposals. All directors nominated for re-election were successfully re-elected to the Board. The stockholders also ratified the appointment of RSM US LLP as the Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis, and the Amended 2012 Plan was also approved.
The most recent analyst rating on (MED) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Medifast stock, see the MED Stock Forecast page.
Spark’s Take on MED Stock
According to Spark, TipRanks’ AI Analyst, MED is a Neutral.
Medifast’s overall stock score reflects significant financial and operational challenges, including declining revenue and negative earnings, despite a strong balance sheet and cash reserves. Technical analysis shows mixed signals, while valuation metrics suggest overvaluation given the current operational losses. The recent earnings call reveals both strategic efforts and ongoing difficulties.
To see Spark’s full report on MED stock, click here.
More about Medifast
Average Trading Volume: 231,524
Technical Sentiment Signal: Sell
Current Market Cap: $155.7M
See more data about MED stock on TipRanks’ Stock Analysis page.